DRG Epidemiology's coverage of AHF comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report the incidence of AHF for each country, as well as annualized case counts projected to the national population.

Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets, and ten years for the other countries covered in this content.

DRG Epidemiology's AHF forecast will answer the following questions:

  • Of all hospitalized AHF events, how many in each country across the major mature pharmaceutical markets are drug-treated?
  • How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of AHF over the forecast period?

All forecast data are available on the DRG Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.

In addition to the total number of cases for each forecast year, DRG Epidemiology also provides at least ten years of forecast data for the following acute heart failure subpopulations:

  • Diagnosed events—AHF primary diagnoses with hypotension.
  • Diagnosed events—AHF primary diagnoses with no hypotension.
  • Diagnosed events— AHF secondary diagnoses with hypotension.
  • Diagnosed events—AHF secondary diagnoses with no hypotension.
  • Diagnosed events—AHF by hypertension status.
  • Diagnosed events—AHF by reduced vs. preserved EF.
  • Diagnosed events—AHF by drug-treatment status.

Note: Coverage may vary by country.

Table of contents

  • Acute Heart Failure - Epidemiology - Mature Markets
    • Introduction
      • Incidence of Acute Heart Failure Events
      • Relative Sizes of Factors Contributing to the Trend in Hospitalization Events of Acute Heart Failure over the Next 20 Years
      • Analysis of Hospitalization Events of Acute Heart Failure in 2017 by Ejection Fraction
      • Analysis of Hospitalization Events of Acute Heart Failure in 2017 by Drug-Treated Status
    • Epidemiology Data
    • Methods
      • Diagnosed Incidence of Acute Heart Failure Events
      • Diagnosed Primary and Secondary AHF Events by Comorbid Hypotension
      • Diagnosed Events of Acute Heart Failure by Comorbid Hypertension
      • Diagnosed Events of Acute Heart Failure by Reduced Ejection Fraction
      • Percentage Drug-Treated
    • Reference Materials
      • Literature Review
        • Studies Included in the Analysis of Acute Heart Failure
        • Studies Excluded from the Analysis of Acute Heart Failure
      • Risk/Protective Factors
        • Risk/Protective Factors for Acute Heart Failure
      • Bibliography

Author(s): Sunali D. Goonesekera, SM

Sunali Goonesekera is an Associate Epidemiologist at Decision Resources Group.

Sunali holds a Master’s degree in Epidemiology from the Harvard School of Public Health and a B.A. in Biology (Honors) from Dartmouth College. Prior to joining Decision Resources Group, Sunali conducted epidemiological research and lead authored two manuscripts on racial/ethnic disparities in metabolic diseases at the New England Research Institutes. She has contributed to multiple publications in peer-reviewed journals in epidemiology and in the biological sciences.


Related Reports

Heart Failure - Landscape & Forecast - Disease Landscape & Forecast

Heart failure (HF) is classified as acute or chronic, and both settings are the focus of this report. Although much progress has been made in the pharmacological...

View Details

Chronic Heart Failure | Preserved Ejection Fraction | Treatment Algorithms | Claims Data Analysis | US | 2020

Although heart failure with preserved ejection fraction (HFpEF) accounts for approximately half of all chronic heart failure cases and even though our understanding of the disease’s pathophysiology...

View Details

Heart Failure - Current Treatment - Detailed, Expanded Analysis: Chronic Heart Failure - Treatment Algorithms: Claims Data Analysis (US)

MARKET OUTLOOK First-line treatment of chronic heart failure (CHF) usually involves an angiotensin-converting enzyme (ACE) inhibitor, an oral beta blocker, and an oral diur...

View Details

Heart Failure | Disease Landscape and Forecast | G7 | 2020

Heart failure (HF) is classified as acute or chronic, and both settings are the focus of this report. Although much progress has been made in the pharmacological management of HF, it mainly relates...

View Details